About Chiltern
Chiltern is a Healthcare company based in Sacramento (United States) founded in 1986, and was acquired by Chiltern International in July 2014. Full-service oncology CRO operations are conducted globally. Chiltern has completed 1 acquisition, including Nexus Oncology. Its focus areas include Biopharma Outsourcing, CRO, Clinical Development and Full Service. Its competitors include Aster Insights, CancerVax and OnCusp; 3 of its 3 listed competitors have raised funding.
Company details
Ockham was a full-service oncology CRO with headquarters in North America and Europe and a presence in 12 countries in 4 continents. The company claims to have conducted 350 oncology-related Phase I-III clinical trials since its inception. Ockhams service portfolio included Scientific Affairs, Clinical Operations, Feasibility, Medical Affairs, Data Management and Biometrics. They catered to the needs of biopharmaceutical and medical device companies trying to develop oncology therapies. Ockham acquired Nexus Oncology, a 120 member strong UK-based oncology CRO, conducting Phase I-III oncology clinical trials across Europe, North America and Australasia in 2012. Post their acquisition by Chiltern, they offer their services through Chiltern Oncology, one of the 3 major divisions of Chiltern.
- Headquarters Sacramento, United States
- Stage Acquired
- SectorsHealthcare
- Website ockham.com
- Social LinkedIn
- Acquired by Chiltern International (Jul 2014)
- Latest Funding Round$4.5M (USD), Debt – Conventional
Jan 2012
- InvestorsChiltern International
& 1 more
- Investments & Acquisitions
- Acquired byChiltern International
(Jul 2014)
Funding Insights of Chiltern
- Total Rounds 1
- Last Round Debt – Conventional β $4.5M
- First Round $4.5M
(Jan 2012)
- Investors Count 1
All 1 funding rounds of Chiltern with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2012 | $4.5M | Debt – Conventional | β | β |
2 investors in total: 2 institutional.
Investors in Chiltern
Chiltern has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Chiltern International and Spring Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Flexible junior capital solutions are offered to growing businesses. | 1999 | springcap.com | Lutherville, United States | |
Full service CRO with expertise in oncology related development services | 1982 | chiltern.com | Berkshire County, United States |
Investor details for Chiltern
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Chiltern
Chiltern has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Nexus Oncology.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Specialist oncology clinical research services for drug trials were provided. | nexusoncology.com | Edinburgh, United Kingdom | 1999 | Jan 2012 | β’β’β’β’ |
Complete acquisition details for Chiltern
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Chiltern
4 dated milestones of Chiltern across 28 years, from founding to its latest funding, stage changes and deals.
- Founded Chiltern is founded.
- Funding First funding round of $4.5M.
- Acquisition Acquires Nexus Oncology.
- Exit Acquired by Chiltern International.
Competitors of Chiltern
Chiltern has 3 listed competitors in our database, 3 of them funded. They include Aster Insights, CancerVax and OnCusp.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| asterinsights.com | 2006 | Tampa, United States | $75M | 115 | Contract-based oncology clinical trial services are provided by Aster Insights. | |
| cancervax.com | 1998 | Carlsbad, United States | $55M | Cancer vaccine research and development is conducted by CancerVax. | ||
| oncusptx.com | 2021 | New York, United States | $100M | CRO offering clinical development services for oncology drugs |
Detailed competitors of Chiltern
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Chiltern
Websites that share an audience with Chiltern (ockham.com).
Websites whose visitors overlap most with Chiltern. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| novellaclinical.com | 100% | View details | |||
| clinipace.com | 96% | View details | |||
| medelis.com | 88% | 4.5K | #4,216,660 | View details |
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Chiltern (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 5,666 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Chiltern
Chiltern was founded in 1986 and raised its 1st funding round 26 years after it was founded.
Chiltern is headquartered in Sacramento, United States. It is registered at Sacramento, California, United States.
Ockham was a full-service oncology CRO with headquarters in North America and Europe and a presence in 12 countries in 4 continents. The company claims to have conducted 350 oncology-related Phase I-III clinical trials since its inception. Ockhams service portfolio included Scientific Affairs, Clinical Operations, Feasibility, Medical Affairs, Data Management and Biometrics. They catered to the needs of biopharmaceutical and medical device companies trying to develop oncology therapies. Ockham acquired Nexus Oncology, a 120 member strong UK-based oncology CRO, conducting Phase I-III oncology clinical trials across Europe, North America and Australasia in 2012. Post their acquisition by Chiltern, they offer their services through Chiltern Oncology, one of the 3 major divisions of Chiltern.
Chiltern's top competitors include CancerVax, OnCusp and Aster Insights.
Chiltern has made 1 acquisition, including Nexus Oncology.
Chiltern has 2 investors. Key investors include Chiltern International, and Spring Capital Partners.
Yes. Chiltern was acquired by Chiltern International in July 2014.
